Join to view full profile
55 Fruit St# MghBoston, MA 02114
Phone+1 617-724-4000
Fax+1 617-643-1915
Dr. Abramson is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Icahn School of Medicine at Mount SinaiClass of 2000
Certifications & Licensure
MA State Medical License 2002 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014, 2017
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014, 2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014, 2017
Clinical Trials
Publications & Presentations
PubMed
- An Electronic Frailty Index Is Associated with Outcomes in Older Adults Receiving CAR-T Therapy.Justine P Enns, Mark R Korst, Nora Horick, Isabel Neckermann, Olivia Y Cheung
Blood Advances. 2026-10-02 - Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.Sairah Ahmed, Alejandro Martín García-Sancho, Juan Luis Reguera Ortega, Guillaume Cartron, Aaron P Rapoport
Blood. 2026-10-01 - Reply to: Biases in the Interpretation of TRANSFORM Circulating Tumor DNA Data: Assessment Timing, Event Definition, and Subset Selection.Lara Stepan, Sahar Ansari, Jeremy S Abramson
Journal of Clinical Oncology. 2026-09-25
Abstracts/Posters
- High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD EvaluationJeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial re...2019 ASCO Annual Meeting - 6/1/2019
- Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene mara...2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People with Relapsed or Refractory Diffuse Large B-cell LymphomaJuly 18th, 2025- Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCLDecember 6th, 2024
- Transplant vs. CAR T in DLBCL: Not Always an Either/Or QuestionOctober 21st, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: